David D Odell1, Joseph Feinglass2, Kathryn Engelhardt3, Steven Papastefan4, Shari L Meyerson5, Ankit Bharat5, Malcolm M DeCamp4, Karl Y Bilimoria6. 1. Northwestern Institute for Comparative Effectiveness Research in Oncology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Feinberg School of Medicine, Chicago, Ill; Surgical Outcomes and Quality Improvement Center, Department of Surgery, Northwestern University, Feinberg School of Medicine, Chicago, Ill; Center for Healthcare Studies, Institute for Public Health and Medicine, Northwestern University, Feinberg School of Medicine, Chicago, Ill; Division of Thoracic Surgery, Department of Surgery, Northwestern University, Feinberg School of Medicine, Chicago, Ill. Electronic address: dodell@nm.org. 2. Northwestern Institute for Comparative Effectiveness Research in Oncology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Feinberg School of Medicine, Chicago, Ill; Department of Medicine, Northwestern University, Feinberg School of Medicine, Chicago, Ill. 3. Northwestern Institute for Comparative Effectiveness Research in Oncology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Feinberg School of Medicine, Chicago, Ill; Surgical Outcomes and Quality Improvement Center, Department of Surgery, Northwestern University, Feinberg School of Medicine, Chicago, Ill; Center for Healthcare Studies, Institute for Public Health and Medicine, Northwestern University, Feinberg School of Medicine, Chicago, Ill. 4. Northwestern Institute for Comparative Effectiveness Research in Oncology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Feinberg School of Medicine, Chicago, Ill; Division of Thoracic Surgery, Department of Surgery, Northwestern University, Feinberg School of Medicine, Chicago, Ill. 5. Division of Thoracic Surgery, Department of Surgery, Northwestern University, Feinberg School of Medicine, Chicago, Ill. 6. Northwestern Institute for Comparative Effectiveness Research in Oncology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Feinberg School of Medicine, Chicago, Ill; Surgical Outcomes and Quality Improvement Center, Department of Surgery, Northwestern University, Feinberg School of Medicine, Chicago, Ill; Center for Healthcare Studies, Institute for Public Health and Medicine, Northwestern University, Feinberg School of Medicine, Chicago, Ill; Division of Surgical Oncology, Department of Surgery, Northwestern University, Feinberg School of Medicine, Chicago, Ill.
Abstract
OBJECTIVE: In this study we present historic data on adherence to and survival outcomes associated with recently introduced quality measures for the management of non-small-cell lung cancer. METHODS: The National Cancer Data Base was queried to identify all patients with non-small-cell lung cancer from 1998 to 2011. Adherence to guidelines was assessed for each of 3 Commission on Cancer-defined quality measures: (1) sampling 10 regional lymph nodes at surgery; (2a) surgery within 120 days of neoadjuvant chemotherapy or, (2b) 180 days of adjuvant chemotherapy; and (3) nonsurgical primary therapy in cN2 disease. The likelihood of measure adherence and the association of measure adherence with all-cause mortality were analyzed controlling for patient, hospital, and time period characteristics. RESULTS: Regional lymph node sampling was inadequate in 72.7% of cases. Only 28.7% began adjuvant chemotherapy within 180 days of surgery. However, 96.5% of patients who received neoadjuvant chemotherapy proceeded to surgery within 120 days and surgery was first-line treatment for cN2 disease in only 3.7% of patients. Uninsured or Medicaid status was an independent risk factor for a prolonged delay between neoadjuvant chemotherapy and surgery (odds ratio, 1.36; 95% confidence interval, 1.08-1.72) and surgery and adjuvant treatment (odds ratio, 1.92; 95% confidence interval, 1.69-2.19). Overall survival was significantly better in patients whose care conformed to quality standards for nodal sampling (measure 1), and timing of chemotherapy. CONCLUSIONS: Adherence rates for nodal sampling at the time of surgery and receipt of adjuvant chemotherapy were low. These findings highlight opportunities for improvement efforts, but more measures are needed to more broadly assess the quality of lung cancer care.
OBJECTIVE: In this study we present historic data on adherence to and survival outcomes associated with recently introduced quality measures for the management of non-small-cell lung cancer. METHODS: The National Cancer Data Base was queried to identify all patients with non-small-cell lung cancer from 1998 to 2011. Adherence to guidelines was assessed for each of 3 Commission on Cancer-defined quality measures: (1) sampling 10 regional lymph nodes at surgery; (2a) surgery within 120 days of neoadjuvant chemotherapy or, (2b) 180 days of adjuvant chemotherapy; and (3) nonsurgical primary therapy in cN2 disease. The likelihood of measure adherence and the association of measure adherence with all-cause mortality were analyzed controlling for patient, hospital, and time period characteristics. RESULTS: Regional lymph node sampling was inadequate in 72.7% of cases. Only 28.7% began adjuvant chemotherapy within 180 days of surgery. However, 96.5% of patients who received neoadjuvant chemotherapy proceeded to surgery within 120 days and surgery was first-line treatment for cN2 disease in only 3.7% of patients. Uninsured or Medicaid status was an independent risk factor for a prolonged delay between neoadjuvant chemotherapy and surgery (odds ratio, 1.36; 95% confidence interval, 1.08-1.72) and surgery and adjuvant treatment (odds ratio, 1.92; 95% confidence interval, 1.69-2.19). Overall survival was significantly better in patients whose care conformed to quality standards for nodal sampling (measure 1), and timing of chemotherapy. CONCLUSIONS: Adherence rates for nodal sampling at the time of surgery and receipt of adjuvant chemotherapy were low. These findings highlight opportunities for improvement efforts, but more measures are needed to more broadly assess the quality of lung cancer care.
Authors: Brandon L Ellsworth; Allan K Metz; Nicole M Mott; Ruby Kazemi; Michael Stover; Tasha Hughes; Lesly A Dossett Journal: Ann Surg Oncol Date: 2022-02-06 Impact factor: 5.344
Authors: Daniel P Nussbaum; Christel N Rushing; Zhifei Sun; Babatunde A Yerokun; Mathias Worni; Robert S Saunders; Mark B McClellan; Donna Niedzwiecki; Rachel A Greenup; Dan G Blazer Journal: Cancer Med Date: 2021-05-04 Impact factor: 4.452
Authors: Scott C Fligor; Savas T Tsikis; Sophie Wang; Ana Sofia Ore; Benjamin G Allar; Ashlyn E Whitlock; Rodrigo Calvillo-Ortiz; Kevin Arndt; Mark P Callery; Sidhu P Gangadharan Journal: J Thorac Dis Date: 2020-11 Impact factor: 2.895
Authors: Rhami Khorfan; David T Cooke; Robert A Meguid; Leah Backhus; Thomas K Varghese; Farhood Farjah; Karl Y Bilimoria; David D Odell Journal: J Thorac Cardiovasc Surg Date: 2020-07-29 Impact factor: 6.439